appendicular sarcoma. Malignant neoplasm of other connective and soft tissue
Conditions
Interventions
Intervention group: Patients who meet the treatment criteria are scheduled for two to four cycles of Lu177-FAPI therapy. Response and adverse events will be assessed after the first two cycles. The pr
Sponsors
Shiraz University of Medical Sciences
Parsisotope Company
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients older than 18 years with unresectable or metastatic limb sarcoma and progressive disease despite standard treatment including chemotherapy, radiotherapy and targeted therapy, or patients with intolerable side effects on available treatments. ECOG>=2 and life expectancy more than 6 months. The patient himself is aware of the disease condition and the status of available treatment options and has approved the informed consent form. Adequate FAPI absorption in the mass. WBC>3000, Hb>9, platelet count>70000, and Cr below 2 times the normal range or GFR>50.
Exclusion criteria
Exclusion criteria: Patients who refused to participate in the study and also had a history of other concurrent cancers or other end-stage organ diseases will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hematologic toxicity. Timepoint: 2-4 weeks after each cycle. Method of measurement: CBC.;Renal toxicity. Timepoint: 2-4 weeks after each cycle. Method of measurement: Serum cratinine.;Response to treatment. Timepoint: After 4 cycles of therapy. Method of measurement: Anatomic imaging and FAPI scan. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTahereh Ghaedian
Shiraz University of Medical Sciences
Outcome results
None listed